Pharmacological interventions to modulate cardiac miR-208a-MED13 signaling or MED13-regulatedcardiokines may provide therapeutically useful avenues in obesity, diabetes, dyslipidemia, and theother systemic metabolic disorders. The gene discussed is MED13; the disease is obesity disorder.